gefitinib + tremelimumab

Gefitinib + tremelimumab is a combination therapy that pairs two distinct mechanisms of action for the treatment of non-small cell lung cancer (NSCLC). Gefitinib is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that blocks ATP binding to EGFR, inhibiting downstream signaling pathways involved in cancer cell proliferation and survival. Tremelimumab is a human monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), blocking its activity and contributing to T-cell activation, thereby enhancing immune response against cancer cells. This combination was specifically studied in EGFR-mutant NSCLC patients who had progressed after first-generation EGFR-TKI therapy.